There are many risk factors for contracting the parasite including living in or traveling to countries where malaria is endemic, not taking the proper precautions such as insect repellent and areas with large amounts of standing water which are sites of mosquito breeding (Centers for Disease Control and Prevention [CDC], 2010). Pathogenes... ... middle of paper ... ...A., Theron, M., Uchikawa, M., & ... Wright, G. (2011). Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature, 480(7378), 534-537. Egan, T. J., & Ross, D. C. (1996).
Some other variations of this parasite are Plasmodium Vivax and Plasmodium Ovale. There is malarial medication available. The most common drug used for treatment of malaria is called chloroquine. Recently it is has been found that Plasmodium Falciparum, the parasite that is responsible for Falciparum malaria, is resistant against chloroquine. This new development in the parasite has caused scientists and doctors to research and come up with new malaria drugs.
P.Ovale, this causes tertian (recurs every second day) malaria in humans. This species is very closely related to both plasmodium falciparum and P.Vivax. P.Ovale has a quite inadequate dispersal. General Life Cycle of the Malaria Parasite: • The female Anopheles mosquito which transmits the malaria parasites feed on the person when the mosquito has pierc... ... middle of paper ... ... to simply stop it from being transported around the body where it will lead to it processing itself to critical stage where it could lead to death, which is the whole reason of why it should be diagnosed and treated by a doctor as soon as possible to eradicate the possibilities of complications and death. Works Cited Carter, Mendis.
There are multiple ideas of how to create such a mosquito. Transgenic mosquito Modified symbiont The transgenic mosquito A transgenic anti-malaria mosquito is a mosquito that has had a gene inserted to make it kill the malaria while it develops in the mosquito. There have been many genes tested, including ... ... middle of paper ... ... the genus Asaia stably associate with Anopheles stephensi, an Asian malarial mosquito vector." Proceedings of the National Academy of Sciences 104(2007): 9047-9051. Li, Chaoyang, Mauro Marrelli, Guiyan Yan, Marcelo Jacobs-Lorena.
Malaria Malaria parasites have been with us since the beginning of time, and fossils of mosquitoes up to thirty million years old show that malaria’s vector has existed for just as long. The parasites causing malaria are highly specific, with man as the only host and mosquitoes as the only vector. Every year, 300,000,000 people are affected by malaria, and while less than one percent of these people die, there are still an estimated 1,500,000 deaths per year. While Malaria was one of the first infectious diseases to be treated successfully with a drug, scientist are still looking for a cure or at least a vaccination today (Cann, 1996). Though many people are aware that malaria is a disease, they are unaware that it is life threatening, kills over a million people each year, and is a very elusive target for antimalarial drugs (Treatment of Malaria, 1996).
Works Cited Journal Gobbi, P., Ferreri, A., Ponzoni, M., Levis, A. (February 2013).Hodgkin lymphoma.Critical Reviews in Oncology/Hematology. (Volume 85, Issue 2, pp. 216-237) Retrieved from http://www.sciencedirect.com.southuniversity.libproxy.edmc.edu/science/article/pii/S1040842812001382 Periodical McBride, D., RN, MSN, CPON. (Sep. 2012).
Symptoms and Diagnosis of Plasmodium Malaria is a disease caused by a protozoan parasite and transported by the Anopheles mosquito. Fever is the most common symptom of malaria. Other symptoms include arthralgia and vomiting. The most common diagnosis process for this disease is looking at the patient’s blood under a microscope. If microscopy is not available, antigen detection tests can be used.
Background: Pneumonia is the leading infectious cause of death in the United States.1 The microorganism most commonly responsible for community-acquired pneumonia (CAP) is S. pneumoniae. Current treatment focuses on eradicating the causative microorganism with antimicrobial therapy.2 Severe CAP often leads to complications such as sepsis and organ failure, such that many patients require mechanical ventilation and admission to the intensive care unit.1 Corticosteroids are currently FDA approved and indicated for the treatment and prophylaxis of asthma.3 The bronchial anti-inflammatory action is achieved through direct inhibition of the mediating cells, including macrophages, T-lymphocytes, and eosinophils. An additional benefit is reduced mucus secretion in airways. These actions spark the question of whether or not there may be a use for corticosteroids in the treatment of CAP. Current American Thoracic Society guidelines recommend corticosteroids only in patients with proven low cortisol levels.4 Interest in systemic corticosteroids has led to studies seeking a possible benefit in reducing mortality in CAP patients.5,6 Literature search strategy: A search was conducted using MEDLINE® via Ovid (1946 to February Week 3 2012).
Introduction Tuberculosis infects over 8 million people per year. Nearly 2 million people die each year from complications due to being plagued with the organism that causes tuberculosis1. Tuberculosis is the second most common cause of death worldwide from an infectious agent1. While incidence numbers are slowly declining with regards to tuberculosis, new barriers to effective treatment are presenting themselves. One such challenge is the emergence of multi-drug resistant (MDR) and extremely drug-resistant (XDR) forms of the disease.